Therapeutic protein-drug interactions: plausible mechanisms and assessment strategies.

about

Label-Free Quantification of Anti-TNF-α in Patients Treated with Adalimumab Using an Optical Biosensor.

P2860

Q55259703-88C3FB75-69B1-4048-B1A3-DBFBED937D50

P2860

Therapeutic protein-drug interactions: plausible mechanisms and assessment strategies.

Item

http://www.wikidata.org/entity/Q40621078

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Therapeutic protein-drug interactions: plausible mechanisms and assessment strategies.

@en

type

Item

label

Therapeutic protein-drug interactions: plausible mechanisms and assessment strategies.

@en

prefLabel

Therapeutic protein-drug interactions: plausible mechanisms and assessment strategies.

@en

P1476

Therapeutic protein-drug interactions: plausible mechanisms and assessment strategies.

@en

P2093

Amarnath Sharma

http://www.w3.org/2001/XMLSchema#string

Honghui Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

Assessment of Disease-Related Therapeutic Protein Drug-Drug Interaction for Etrolizumab in Patients With Moderately to Severely Active Ulcerative Colitis

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.

Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics

Active efflux of ciprofloxacin from J774 macrophages through an MRP-like transporter.

Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis.

P31

scholarly article

P356

10.1080/17425255.2016.1211109

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2016-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27391296

http://www.w3.org/2001/XMLSchema#string

Therapeutic protein-drug interactions: plausible mechanisms and assessment strategies.

about

P2860

P2860

Therapeutic protein-drug interactions: plausible mechanisms and assessment strategies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P577

P698

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P577

P698